1. Scrip

ASCO: BeiGene, Novartis Herald Global PD-1 Contender In ESCC

Filings Approaching

 
• By Dexter Jie Yan and John Davis

The Chinese biotech is set to extend the reach of its PD-1 candidate to the global market with a second major clinical win and following an earlier major deal with Novartis.

Magnifying lens over background with text Immuno-oncology, with the blurred lights visible in the background. 3D rendering.
More Progress For BeiGene's Immuno-Oncology Pipeline • Source: Shutterstock

BeiGene, Ltd. has provided detailed findings from a global Phase III trial for its anti-PD-1 antibody BaizeAn (tislelizumab) for the treatment of esophageal squamous cell carcinoma (ESSC). 

The numerical results marked further recent major clinical progress for the Beijing-based Chinese biotech's flagship checkpoint inhibitor, which it

More from ASCO

More from Conferences